Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11491285 | 0.78 | RXFP1 (0.36) | RXFP1HPGDPOLBDAOALDH1A1 | |
| SCHEMBL21957490 | 0.75 | HSD17B10 (0.36) | RXFP1HPGDPOLBALDH1A1KDM4E | |
| SCHEMBL2285407 | 0.73 | HSD17B10 (0.35) | HPGDALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL11489305 | 0.73 | MAPT (0.43) | RXFP1HPGDPOLBDAOALDH1A1 | |
| SCHEMBL15015960 | 0.71 | P2RX3 (0.47) | HPGDPOLBALDH1A1KDM4EGAA | |
| SCHEMBL5565965 | 0.71 | POLB (0.38) | HPGDPOLBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29012451 | 0.71 | HSD17B10 (0.33) | HPGDALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL15474117 | 0.70 | — | — | |
| SCHEMBL3555531 | 0.69 | POLB (0.59) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL11200904 | 0.69 | ALDH1A1 (0.39) | HPGDPOLBDAOALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582655-B2 | Methods of treating disorders using CSFIR inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260034131-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2026-02-05 | — | — | US | disclosed |
| US-12485120-B2 | Methods of treating disorders using CSF1R inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4647767-A2 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4303583-B1 | CSF1R INHIBITORS FOR USE IN TREATING TENOSYNOVIAL GIANT CELL TUMORS | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250205237-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| US-12285430-B2 | Methods of treating disorders using CSF1R inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-04-29 | — | — | US | disclosed |
| CN-118453610-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118453609-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118453608-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1827434-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | Amgen Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034131-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | CSF1R, CSF3R, ARG1 | RXFP1 1469/4885HPGD 3595/4885POLB 3469/4885 |
| US-12485120-B2 | Methods of treating disorders using CSF1R inhibitors | CSF1R, CSF3R, CD68 | RXFP1 2102/4885HPGD 3238/4885POLB 3711/4885 |
| US-20250205237-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | CSF1R, CSF3R, CD68 | RXFP1 2102/4885HPGD 3238/4885POLB 3711/4885 |
| US-12582655-B2 | Methods of treating disorders using CSFIR inhibitors | CSF1R, CSF3R, MSR1 | RXFP1 1433/4885HPGD 2976/4885POLB 3081/4885 |
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | RXFP1 3711/4885HPGD 41/4885POLB 1242/4885 |
| US-12285430-B2 | Methods of treating disorders using CSF1R inhibitors | CSF1R, CSF3R, CD68 | RXFP1 2102/4885HPGD 3238/4885POLB 3711/4885 |
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | RXFP1 88/4885HPGD 1056/4885POLB 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.